Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

956
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
956
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

582
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
582
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

850
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
850

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Ex vivo</i> perfusion model of mouse liver and its application to analyze the effects of OCT1 deficiency.

Frontiers in pharmacology·2025
Same author

The organic cation transporters 1 and 2 mediate ethanolamine cellular efflux and control systemic phosphatidylethanolamine level.

The Journal of biological chemistry·2025
Same author

Guilty by association: direct interaction with the tetraspanin CD63 suggests a role for organic cation transporter 3 in histamine release from granulocytes.

Journal of biomedical science·2025
Same author

Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients.

Breast cancer research : BCR·2025
Same author

Regulation of renal organic cation transporters.

FEBS letters·2024
Same author

Overcoming Biological Barriers: Importance of Membrane Transporters in Homeostasis, Disease, and Disease Treatment 2.0.

International journal of molecular sciences·2024

Related Experiment Video

Updated: May 7, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

8.8K

Saving ears and kidneys from cisplatin.

Kristina U Wensing1, Giuliano Ciarimboli

  • 1Medizinische Klinik D, Experimentelle Nephrologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A14, 48149 Münster, Germany. gciari@uni-muenster.de.

Anticancer Research
|October 15, 2013
PubMed
Summary

Cisplatin

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Toxicology

Background:

  • Cisplatin is a vital chemotherapy drug with significant nephro-, oto-, and neurotoxicity.
  • Drug transporters mediate cellular uptake of cisplatin, influencing its efficacy and toxicity.
  • Understanding transporter roles is key to mitigating cisplatin's adverse effects.

Purpose of the Study:

  • Investigate the role of specific transporters in cisplatin uptake.
  • Explore strategies to reduce cisplatin-induced organ toxicities by targeting these transporters.
  • Identify potential targets for protective therapies against cisplatin toxicity.

Main Methods:

  • Review of existing literature on cisplatin transporters.
  • Focus on Copper transporter-1 (Ctr1) and Organic Cation Transporter 2 (OCT2) in cisplatin transport.
Keywords:
Transporterscisplatinprotectionreviewtoxicitytumoruptake

More Related Videos

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

7.4K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

13.2K

Related Experiment Videos

Last Updated: May 7, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

8.8K
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

7.4K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

13.2K
  • Analysis of transporter expression patterns in normal and tumor cells.

    • Main Results:

    • Ctr1 facilitates general cisplatin uptake in both tumor and normal cells.
    • OCT2 is primarily expressed in critical organs like kidneys, cochlea, and nerves.
    • OCT2 expression is reduced in some tumors, suggesting tissue-specific roles.

    Conclusions:

    • Targeting OCT2 for inhibition could reduce cisplatin uptake in non-target organs.
    • Specific OCT2 inhibition may protect against cisplatin toxicity without affecting its anti-tumor activity.
    • OCT2 represents a promising target for developing protective therapies against cisplatin-associated toxicities.